Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti-CD19-AntiCD3 Diabody
GP101 is a single chain diabody composed of Fv regions of antibodies directed to CD3 and CD19. It is designed to mimic commercial blinatumomab (Blincyto(R)) that simultaneously co-engages patient T lymphocytes and CD19 positive B cell leukemias and lymphomas, facilitating their targeted destruction. This study details the purification of GP101 protein and development of a highly sensitive ELISA for its detection, achieving a sensitivity of 15pg/mL in 25% mouse serum. This ELISA has been validated according to GLP standards.
immunology↗